Results 21 to 30 of about 5,560 (153)

Aprepitant inhibits the progression of esophageal squamous cancer by blocking the truncated neurokinin‑1 receptor

Oncology Report, 2023
Increasing evidence showed that the substance P (SP)/neurokinin-1 receptor (NK1R) complex is involved in the development of several cancers. However, little is known about the mechanisms by which SP/NK1R complex plays a role in esophageal squamous cell ...
Yang Zheng, Meixiang Sang, Fei Liu, L. Gu, Juan Li, Yunyan Wu, B. Shan   +6 more
semanticscholar   +1 more source

Asymmetric Catalytic Access to Piperazin-2-ones and Morpholin-2-ones in a One-Pot Approach: Rapid Synthesis of an Intermediate to Aprepitant

Journal of Organic Chemistry, 2023
A one-pot Knoevenagel reaction/asymmetric epoxidation/domino ring-opening cyclization (DROC) has been developed from commercial aldehydes, (phenylsulfonyl)acetonitrile, cumyl hydroperoxide, 1,2-ethylendiamines, and 1,2-ethanol amines to provide 3-aryl ...
Sara Meninno, A. Lattanzi
semanticscholar   +1 more source

Assessing the impact of aprepitant and ondansetron on postoperative nausea and vomiting in orthognathic surgeries: a randomized controlled trial

BMC Anesthesiology, 2023
Background Postoperative nausea and vomiting (PONV) is a common side effect associated with general anesthesia. Both ondansetron and aprepitant been effectively used to prevent PONV.
Mostafa Alam, Alireza Shakeri, Ardeshir Khorsand, K. Nasseri, Sadaf Nasseri   +4 more
semanticscholar   +1 more source

Efficacy and safety of Aprepitant-containing triple therapy for the prevention and treatment of chemotherapy-induced nausea and vomiting: A meta-analysis

Medicine, 2023
Background: Most cancer patients suffer from the pain of chemotherapy-induced nausea and vomiting (CINV). This meta-analysis was performed to evaluate the efficacy and safety of a regimen consisting of aprepitant, dexamethasone, and 5-HT3 receptor ...
Min Zhang, Qingli Guo, Tingting Zhang, Min Fu, Hengtai Bi, Junyao Zhang, Kaili Zou   +6 more
semanticscholar   +1 more source

Biological evaluation of carbohydrate-based aprepitant analogs for neuroblastoma treatment.

European journal of medicinal chemistry, 2023
Different studies using Aprepitant, a NK1R antagonist currently used as a clinical drug for treating chemotherapy-related nausea and vomiting, have demonstrated that pharmacological inhibition of NK1R effectively reduces the growth of several tumor types
V. Valdivia, R. Recio, Patricia Lerena, Esther Pozo, Rosario Serrano, Raúl Calero, Cristina Pintado, Manuel Pernia Leal, Nazaret Moreno-Rodríguez, J. A. Organero, Noureddine Khiar, I. Fernández   +11 more
semanticscholar   +1 more source

Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant Interaction

Clinical pharmacology and therapy, 2023
All patients treated with anticancer agents should receive the most effective anti‐emetic regimen. Anti‐emetic guidelines provide recommendations but do not take into account possible drug–drug interactions between anti‐emetics and anticancer drugs. This
J. Strik, L. D. de Jong, Joost Sijm, I. Desar, N. V. van Erp   +4 more
semanticscholar   +1 more source

Population pharmacokinetic analysis reveals no impact of aprepitant on the pharmacokinetics of ifosfamide, 2-dechloroifosfamide, and 3-dechloroifosfamide.

European Journal of Pharmaceutical Sciences, 2023
PURPOSE Several case reports and retrospective series have clearly pointed to the role of aprepitant, an antiemetic drug, in the development of encephalopathy when used with ifosfamide.
T. Valentin, M. Lambert, L. Chaltiel, Ben C. Allal, Mourad Mseddi, Malika Yakoubi, C. Chevreau, M. Toulmonde, N. Firmin, T. Filleron, E. Chatelut   +10 more
semanticscholar   +1 more source

Review of nutrition management of pediatric intestinal pseudo‐obstruction

Nutrition in Clinical Practice, EarlyView.
Abstract Chronic intestinal pseudo‐obstruction (CIPO) is a rare, heterogeneous, and debilitating disorder characterized by profound intestinal dysmotility and severe nutrition challenges. Its presentation resembles that of mechanical bowel obstruction, but CIPO occurs in the absence of luminal obstruction.
Senthilkumar Sankararaman, Raisa Rani James, Bushra El‐Amaireh, Andrea Adler, Kadakkal Radhakrishnan, Sujithra Velayuthan   +5 more
wiley   +1 more source

GA&HA-Modified Liposomes for Co-Delivery of Aprepitant and Curcumin to Inhibit Drug-Resistance and Metastasis of Hepatocellular Carcinoma

International Journal of Nanomedicine, 2022
Background Tumor microenvironment (TME) plays a vital role in the development of hepatocellular carcinoma (HCC). Mounting evidence indicates that peripheral nerves could induce a shift from quiescent hepatic stellate cells (HSCs) to cancer-associated ...
Yanying Li, Jing-liang Wu, Q. Lu, Xuemin Liu, Jiaxuan Wen, Xiaohui Qi, Jianhao Liu, Bo Lian, Bo Zhang, Hengyi Sun, Guixiang Tian   +10 more
semanticscholar   +1 more source

Advent of NK3R Antagonists for the Treatment of Menopausal Hot Flushes: A Narrative Review

BJOG: An International Journal of Obstetrics &Gynaecology, EarlyView.
ABSTRACT The menopause transition is marked by symptoms predominantly attributed to declining oestrogen levels. Approximately 80% of women experience associated symptoms, and 25% experience severe symptoms. The commonest are vasomotor symptoms (VMS), collectively referring to hot flushes and/or night sweats.
Aaran H. Patel, Aureliane Pierret, Edouard G. Mills, Alexander N. Comninos, Waljit S. Dhillo, Ali Abbara   +5 more
wiley   +1 more source